Search clinical trials for: E7820

Total 6 results

Eisai Inc.

Completed

An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors

Advanced Solid Tumors

Netherlands, United Kingdom
Memorial Sloan Kettering Cancer Center
Eisai Inc.

Active, not recruiting

A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
Eisai Inc.

Completed

Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma

Neoplasms | Lymphoma, Malignant

United States
Eisai Inc.

Completed

A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors

Advanced Colorectal Cancer

United States, Canada
Eisai Inc.
PharmaBio Development Inc.

Terminated

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Rectal Cancer | Colon Cancer

Argentina, Russian Federation, United States, Australia, Brazil, Ukraine
Eisai Inc.
Quintiles, Inc.

Terminated

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

United States, Australia, Russian Federation, India, Ukraine

3

Subscribe